Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 7Withdrawn 2Terminated 2Active not recruiting 2Unknown 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2Lymphoid 2Sarcoma 1Myeloid 1

Conditions

Multiple Myeloma 2Neoplasms, Plasma Cell 1

Interventions

Dexamethasone 130Lenalidomide 82daratumumab 60Bortezomib 56carfilzomib 45Calcium Dobesilate 41pomalidomide 37Cyclophosphamide 31isatuximab 26belantamab mafodotin 23Specimen Handling 21Biopsy 21Magnetic Resonance Spectroscopy 18dexamethasone acetate 16dexamethasone 21-phosphate 16ixazomib 15auricularum 15fludarabine 13Melphalan 13iberdomide 11elotuzumab 11selinexor 10fludarabine phosphate 9X-Rays 8talquetamab 7venetoclax 6trametinib 6nirogacestat 6Whole-Body Irradiation 6Thalidomide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Transplantation × Plasma cell × Clear all
NCT06126341 2026-02-19

A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders

Memorial Sloan Kettering Cancer Center

Active not recruiting
49 enrolled
Plasma cell

Multiple Myeloma

NCT01208662 2026-01-22

DFCI 10-106

Dana-Farber Cancer Institute

Phase 3 Active not recruiting
729 enrolled 29 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡